Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Why Johnson & Johnson Might Be the Smartest Dividend King to Buy in Today's Market
05:15pm, Monday, 25'th May 2026
Johnson & Johnson is a leader in the pharmaceutical and medical device markets. Consumers don't usually have many choices when it comes to their medical care.
What a $1 Million Dividend Portfolio Actually Pays After Federal AND State Taxes in California
11:19am, Monday, 25'th May 2026
A California retiree with a $1 million dividend portfolio earning a 5% blended yield grosses $50,000 in annual income.
Two Paths to Growth: Johnson & Johnson vs AbbVie
07:47am, Monday, 25'th May 2026
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that beat revenue expectations and prompted raised full-year guidance.
The Single Premium Immediate Annuity That Adds $3,800 a Month to a $1.2 Million Income Portfolio Without Touching a Stock
10:27am, Saturday, 23'rd May 2026
A 73-year-old retiree with a $1.2 million dividend portfolio generating $5,400 a month faces a quieter retirement problem than most. The income works, but it depends on corporations continuing to pay
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
04:41pm, Friday, 22'nd May 2026
Innovation, regulatory policy, and demographics are driving healthcare stocks higher. Healthcare companies have also posted strong first-quarter results.
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned?
11:05am, Friday, 22'nd May 2026
JNJ's diversified pharma and MedTech growth, pipeline progress and stronger 2026 outlook give it an edge over PFE.
The Dividend Stocks That Can Replace a $65,000 Income and What They'll Cost You
07:36am, Friday, 22'nd May 2026
Dividend-growth blue chips like Coca-Cola double income in nine years despite lower starting yields, while high-yield BDCs and REITs with frozen payouts risk delivering less income over a decade than
Six Boring Blue Chips Generate $54,000 a Year on $920,000 Without a Single 7 Percent Yield Trap
07:15am, Friday, 22'nd May 2026
The six names below sit firmly in the conservative-to-moderate tier. Five are Dividend Kings or Aristocrats.
Johnson & Johnson (JNJ) Outperforms Broader Market: What You Need to Know
06:46pm, Thursday, 21'st May 2026
In the latest trading session, Johnson & Johnson (JNJ) closed at $231.73, marking a +1.05% move from the previous day.
A Dividend Portfolio That Beats the Median Household Income in 47 of the 50 States on $1.1 Million Invested
11:57am, Thursday, 21'st May 2026
The U.S. median household income sits near $80,610, and a $1.1 million dividend portfolio generating a blended 7% yield would produce roughly $77,000 a year in cash flow. That level of income exceeds
If Treasury Yields Jump Above 4.75%, Here’s What Happens to SDY
11:45am, Thursday, 21'st May 2026
The SPDR S&P Dividend ETF (NYSEARCA:SDY) is doing exactly what a yield-tilted dividend fund is supposed to do while the broader market wobbles: grinding higher while the broad market wobbles. SDY trad
A $400,000 Income Portfolio That Pays Like a Toledo Rental Property Without the 3 AM Phone Calls
07:37am, Thursday, 21'st May 2026
A single-family rental property in Toledo purchased for $135,000 at a 9% gross cap rate would generate roughly $12,150 annually in gross rental income. After accounting for property taxes, insurance,
Johnson & Johnson Advances Creation of Global Intelligent OR Network in collaboration with Department of Health - Abu Dhabi
07:00am, Thursday, 21'st May 2026
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced a collaboration with the Department of Health – Abu Dhabi (DOH), the regulator of the healthcare sector in Abu Dhabi, UAE, lau
A Monthly Dividend Portfolio That Pays Like a Pension and Beats Most Pensions on Inflation Protection
06:59am, Thursday, 21'st May 2026
A traditional defined-benefit pension paying $5,500 per month, or $66,000 annually, provides a useful retirement-income benchmark. That level of income sits near the upper range of what many private-s
Johnson & Johnson says nipocalimab approved in China
04:31am, Thursday, 21'st May 2026
Johnson & Johnson's nipocalimab has won approval in China, the U.S. drugmaker said on its WeChat social media account Thursday.
